{"id":"adalimumab-gp2017","safety":{"commonSideEffects":[{"rate":"10–20%","effect":"Injection site reactions"},{"rate":"10–15%","effect":"Upper respiratory tract infections"},{"rate":"5–10%","effect":"Headache"},{"rate":"1–3%","effect":"Serious infections (including tuberculosis)"},{"rate":"low, similar to reference product","effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a TNF-α inhibitor, GP2017 blocks the interaction between TNF-α and its receptors on immune cells and tissue, thereby suppressing the inflammatory cascade. This mechanism is used to treat autoimmune and inflammatory conditions where TNF-α plays a pathogenic role. GP2017 is a biosimilar copy of the reference biologic adalimumab (Humira), designed to have equivalent efficacy and safety.","oneSentence":"GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:31.560Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"}]},"trialDetails":[{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02016105","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-12","conditions":"Plaque Type Psoriasis","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GP2017"],"phase":"phase_3","status":"active","brandName":"Adalimumab - GP2017","genericName":"Adalimumab - GP2017","companyName":"Sandoz","companyId":"sandoz","modality":"Biologic","firstApprovalDate":"","aiSummary":"GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}